SenzaGen Newsletter October 2024
As a leading innovator in skin sensitization testing, SenzaGen continues to work closely with industry leaders, exploring the potential of our cutting-edge GARD? technology. Discover more about these exciting advancements in our latest newsletter.
Insights from industry-leading experts at Eurotox 2024
At this year's Eurotox in Copenhagen, we were delighted to have experts from Lundbeck and Unilever joining us to discuss the latest advancements in skin sensitization testing. During the event, we also unveiled exciting GARD? updates from collaborative projects, including those of Cargill and ExxonMobil Biomedical Sciences.
New publication: Prediction of PoD for Quantitative Risk Assessment
In collaboration with L'Oréal’s scientific team, SenzaGen has co-authored a peer-reviewed article in Toxics (MDPI). The paper highlights the effectiveness of the GARD?skin Dose-Response assay in Quantitative Risk Assessment.The study, which involved 30 chemicals and a composite potency model, demonstrates the assay’s ability to predict a Point-of-Departure (PoD) for potential skin sensitizers, showing concordance with NESIL values derived from LLNA and Human data. This is a key advancement in enhancing risk assessment strategies for chemical safety.
Top chemical company adopts GARD? to establish safe dose levels
We are excited to announce that another leading chemical company has adopted the GARD?skin Dose-Response assay to determine safe dose levels for specialty chemicals in their product development, as an alternative to animal testing.?
Advancing assay development for Photosensitization
Our collaboration with RIFM is set to expand to further develop the GARD?skin Dose-Response method for identifying photoallergens. This initiative aims to deliver quantitative insights into skin sensitization, helping to differentiate photoallergens from photoirritants, which is crucial for safety in cosmetics and chemicals.